At the news
? BEARISHIMPACT 5/10 COURT-RULING filed May 27, 2026 at 20:00 ET
A federal magistrate judge in Delaware recommended denying Illumina's motion to dismiss Element Biosciences' patent infringement lawsuit, ruling that the § 101 patent-eligibility challenge to the '161 Patent is premature at the pleading stage. The court found both parties' briefing inadequate and noted that claim narrowing will occur as the case progresses, allowing Illumina to renew its motion at summary judgment. This keeps the patent case alive and preserves Element's infringement claims, extending litigation uncertainty for Illumina.
- Element Biosciences sued Illumina on September 22, 2025, alleging infringement of four patents (U.S. Patent Nos. 8,612,161, 9,605,301, 9,909,174, and 11,001,887).
- Illumina moved to dismiss all 38 claims of the '161 Patent as directed to ineligible subject matter under 35 U.S.C. § 101.
- The magistrate judge recommended DENYING the motion to dismiss without prejudice to renew at summary judgment, citing inadequate briefing and the likelihood of claim narrowing.
- The ruling is a Report and Recommendation; objections are due within 14 days (by June 11, 2026).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access